- PII
- S19982860S0132342325040126-1
- DOI
- 10.7868/S1998286025040126
- Publication type
- Article
- Status
- Published
- Authors
- Volume/ Edition
- Volume 51 / Issue number 4
- Pages
- 678-687
- Abstract
- The work is devoted to the comparison of alternative piperidine deblocking agents using the examples of solid-phase synthesis of ingramon, which has anti-inflammatory activity, and methylin, an agonist of the transmembrane API receptor. The possibility of using these peptides for the treatment of cardiovascular diseases dictates the need to develop optimized methods for their synthesis. Particular attention in the work is paid to the choice of a reagent for removing Fmoc protection in solid-phase peptide synthesis, which would ensure a high yield and purity of the target product with a minimum amount of related impurities. In the synthesis of the aspartyl peptide ingramon, the lowest content of by-products was noted when using a mixture containing 10% piperazine for cleaving the Fmoc protection. In addition, piperazine is an accessible and low-toxic reagent, which is attractive for large-scale solid-phase peptide synthesis. In the synthesis of methylin, the maximum yield of the product was obtained using a deblocking mixture based on pyrrolidine. The selected deblocking reagents can successfully replace toxic piperidine in solid-phase peptide synthesis not only in the laboratory but also in the preparative scale. These reagents can find application in obtaining peptide pharmaceutical substances.
- Keywords
- твердофазный синтез пептидов реагенты для отщепления Fmoc-группы инграмон метиллин образование аспартимида образование дихетопиперазина 4-метилпиперидин пирролидин пиперазин
- Date of publication
- 15.02.2025
- Year of publication
- 2025
- Number of purchasers
- 0
- Views
- 10
References
- 1. Vlieghe P., Lisowski V., Martinez J., Khrestchatsky M. // Drug Discov. Today. 2010. V. 15. P. 40–56. https://doi.org/10.1016/j.drudis.2009.10.009
- 2. Fosgerau K., Hoffmann T. // Drug Discov. Today. 2015. V. 20. P. 122–128. https://doi.org/10.1016/j.drudis.2014.10.003
- 3. de la Torre B.G., Albericio F. // Molecules. 2023. V. 28. P. 1038. https://doi.org/10.3390/molecules28031038
- 4. Bruckdorfer T., Marder O., Albericio F. // Curr. Pharm. Biotechnol. 2004. V. 5. P. 29–43. https://doi.org/10.2174/1389201043489620
- 5. Behrendt R., White P., Offer J. // J. Pept. Sci. 2016. V. 22. P. 4–27. https://doi.org/10.1002/psc.2836
- 6. Li W., O’Brien-Simpson N.M., Hossain M.A., Wade J.D. // Aust. J. Chem. 2020. V. 73. P. 271–276. https://doi.org/10.1071/CH19427
- 7. Fmoc Solid Phase Peptide Synthesis. A Practical Approach / Eds. Chan W.C., White P.D. Oxford University Press, 1999. https://doi.org/10.1093/oso/9780199637256.001.0001
- 8. Carpino L.A. // Acc. Chem. Res. 1987. V. 20. P. 401–407.
- 9. Luna O.F., Gomez J., Cárdenas C., Albericio F., Marshall S.H., Guzmán F. // Molecules. 2016. V. 21. P. 1542. https://doi.org/10.3390/molecules21111542
- 10. Drug Enforcement Administration (DEA), Department of Justice. Control of immediate precursor used in the illicit manufacture of fentanyl as a schedule II controlled substance. Final rule. Fed Regist. 2010. V. 75. P. 37295–37299. https://www.federalregister.gov/documents/2010/06/29/2010-15520/control-of-immediate-precursor-used-in-the-illicit-manufacture-of-fentanyl-as-a-schedule-ii
- 11. List of Precursors and chemicals Frequently used in the illicit manufacture of narcotic drugs and psychotropic substances under International Control. https://inch.org/documents/PRECURSORS/RED_LIST/2020/Red_List_2020_E.pdf
- 12. Петросянц М.В., Палькеева М.Е., Молокоедов А.С., Овчинников М.В., Сидорова М.В. // Хим.-фарм. журн. 2024. T. 58. C. 38–43. https://doi.org/10.30906/0023-1134-2024-58-3-38-43
- 13. Sidorova M.V., Molokoedov A.S., Aref’eva T.I., Kukhtina N.B., Krasnikova T.I., Bespalova Zh.D., Bushuev V.N. // Russ. J. Bioorg. Chem. 2004. V. 30. P. 523–533. https://doi.org/10.1023/B:RUBl.0000049768.98894.f5
- 14. Sidorova M.V., Az’muko A.A., Pal’keeva M.E., Molokoedov A.S., Bushuev V.N., Dvoryantsev S.N., Shulzhenko V.S., Pelogeykina Y.A., Pisarenko O.I., Bespalova Zh.D. // Russ. J. Bioorg. Chem. 2012. V. 38. P. 30–40. https://doi.org/10.1134/S1068162012010177
- 15. Lauer L.L., Fields C.G., Fields G.B. // Lett. Pept. Sci. 1995. V. 1. P. 197–205.
- 16. Yang Y., Hansen L. // ACS Omega. 2022. V. 7. P. 12015–12020. https://doi.org/10.1021/acsomega.2c00214
- 17. Wade J.D., Mathieu M.N., Macris M., Tregear G.W. // Lett. Pept. Sci. 2000. V. 7. P. 107–112. https://doi.org/10.1023/A:1008966207751
- 18. Sidorova M.V., Dudkina U.S., Avdeev D.V., Palkeeva M.E., Molokoedov A.S., Ovchinnikov M.V., Azmuko A.A., Bushuev V.N., Arefava T.I., Grechishnikov S.B., Kudryavtseva E.V. // Russ. J. Bioorg. Chem. 2020. V. 46. P. 520–529. https://doi.org/10.1134/S1068162020040202
- 19. Craveur P., Joseph A.P., Poulain P., de Brevern A.G., Rebehmed J. // Amino Acids. 2013. V. 45. P. 279–289. https://doi.org/10.1007/s00726-013-1511-3
- 20. Pedroso E., Grandas A., de las Herasl X., Eritja R., Giralt E. // Tetrahedron Lett. 1986. V. 27. P. 743–746.
- 21. pK data compiled by Williams R. American Chemical Society, Organic Division, 2022. https://organicchemistrydata.org/hansreich/resources/pka/
- 22. Eissler S., Kley M., Bächle D., Loidl G., Meiera T., Samson D. // J. Pept. Sci. 2017. V. 23. P. 757–762. https://doi.org/10.1002/psc.3021
- 23. Szczepanska E., Grobelna B., Ryl J., Kalpa A., Ossowski T., Niedzialkowski P. // Molecules. 2020. V. 25. P. 3983. https://doi.org/10.3390/molecules25173983
- 24. Knorr R., Trzeciak A., Bannwarth W., Gillessen D. // Tetrahedron Lett. 1989. V. 30. P. 1927–1930.
- 25. Ralhan K., Krishnakumar V.G., Gupta Sh. // RSC Adv. 2015. V. 5. P. 104417. https://doi.org/10.1039/c5ra23441g
- 26. Barlos K., Gatos D. // Convergent Peptide Synthesis. In: Fmoc Solid Phase Peptide Synthesis. A Practical Approach / Eds. Chan W.C., White P.D. Oxford University Press, 2000. P. 215–228.
